Immigration isn't on the to-do lists for American biopharma lobbyists, and it apparently isn't on the radar screens of most industry leaders in the U.S. They may be surprised to learn that Congress stands ready to discriminate against life scientists trained with NIH dollars but born somewhere else.

BioCentury stands at the head of the line when it comes to advocating the globalization of bioscience, with the benefits it will provide everywhere in terms of public health, jobs and national wealth. But that does not mean taking the U.S. for granted, especially when politics has produced wrong-headed ideas that now threaten to explicitly discriminate against talent that the biopharma industry needs to drive innovation.